M&A / Deals Beren pockets $300m to take Niemann-Pick disease therapy to market Pharmaceutical TechnologyIf approved, Beren's adrabetadex would join Zevra Therapeutics' Miplyffa and IntraBio's Aqneursa on the I-NPC market.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 15, 2026) Pharmaceutical Technology If approved, Beren’s adrabetadex would join Zevra Therapeutics’ Miplyffa and IntraBio’s Aqneursa on the I-NPC market. Rare Disease Read full story Post navigation Previous: Aquipta recommended by NICE for acute migraine treatmentNext: Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026